-
With a pair of compounds acquired from an Indian pharma, Allecra aims to develop a broad-spectrum solution to multidrug resistant Gram-negative bacteria.
Published on 5/13/2013
-
Allecra: Secret weapon vs. bacteria Allecra Therapeutics GmbH Lorrach, Germany Technology: Antimicrobials for drug-resistant bacteria Disease focus: Infectious Clinical status: Preclinical Founded: 2013 by …
Published on 5/13/2013
-
Ultimovacs: hTERT redux Ultimovacs AS Oslo, Norway Technology: Peptide-based therapeutic cancer vaccines Disease focus: Cancer Clinical status: Phase I/IIa Founded: 2011 by Gustav Gaudernack, Else Marit …
Published on 5/13/2013
-
Ultimovacs is developing a telomerase-based cancer vaccine that could treat a much broader range of cancer patients than a first-generation vaccine now in the clinic.
Published on 5/13/2013
-
Neurotrope: Saving synapses Neurotrope BioScience Inc. Plantation, Fla. Technology: Small molecule activators of protein kinase C isozymes Disease focus: Neurology Clinical status: Phase II Founded: 2012 by John…
Published on 5/6/2013
-
Neurotrope is developing Alzheimer's therapeutics targeting protein kinase C, an enzyme that could play a central role in pathology upstream of amyloid plaques and neurofibrillary tangles.
Published on 5/6/2013
-
Avilex: One-two pain punch Avilex Pharma ApS Copenhagen, Denmark Technology: Dimeric inhibitor of PSD95 Disease focus: Neurology Clinical status: Preclinical Founded: 2013 by Anders Bach and Kristian Stromgaard…
Published on 4/29/2013
-
Avilex's dimeric inhibitor of PSD95 could offer a potent treatment for chronic pain without cognitive side effects of other approaches in NMDA pathway.
Published on 4/29/2013
-
TissUse: Human on a chip TissUse GmbH Berlin, Germany Technology: Chip that contains organoids Disease focus: Microtissue arrays Clinical status: Preclinical Founded: 2010 by Uwe Marx, Gerd Lindner, Heike Walles…
Published on 4/29/2013
-
TissUse is developing a chip that contains multiple miniature organoids that might supplement or replace some preclinical and clinical testing.
Published on 4/29/2013
-
Cardiorentis is the fifth company to try ularitide for acute heart failure. It expects to succeed thanks to a big war chest and reduced clinical trial requirements in the EU.
Published on 4/22/2013
-
Cardiorentis: Keeping heart Cardiorentis AG Zug, Switzerland Technology: Ularitide synthetic urodilatin Disease focus: Cardiovascular Clinical status: Phase III Founded: 2010 by undisclosed founders University …
Published on 4/22/2013
-
SiteOne is developing state-independent sodium channel inhibitors for non-narcotic pain relief that it expects to confer advantages in potency, selectivity and solubility.
Published on 4/22/2013
-
SiteOne's saxy synthesis SiteOne Therapeutics Inc. Redwood City, Calif. Technology: Targeting sodium channels to develop non-narcotic pain medicines and diagnostics for neuronal pain generators Disease focus: …
Published on 4/22/2013
-
Abcodia: Banking on biomarkers Abcodia Ltd. London, U.K. Technology: Biomarkers for cancer screening Disease focus: Diagnostic Clinical status: Pivotal Founded: 2011 by Julie Barnes, Chris Hodkinson, Andy …
Published on 4/15/2013
-
Abcodia is using a bank of annually taken blood samples to identify serum biomarkers that can detect breast, lung, pancreatic and colorectal tumors at least a year before symptomatic presentation.
Published on 4/15/2013
-
Syros is mapping 'super-enhancers' of the transcriptional regulatory circuits that define cancer cell identity, and aims to use small molecules to selectively disrupt them.
Published on 4/15/2013
-
Syros: Super maps Syros Pharmaceuticals Inc. Watertown, Mass. Technology: Mapping and disrupting disease-associated gene regulatory networks Disease focus: Cancer, genomics Clinical status: Discovery Founded: …
Published on 4/15/2013
-
MAB Discovery: Monitoring maturation MAB Discovery GmbH Neuried, Germany Technology: In vivo mAb discovery using wild-type rabbits and rats, and B cell cloning Disease focus: NA Clinical status: NA Founded: 2010…
Published on 4/8/2013
-
MAB Discovery uses blood samples taken at multiple time points during antibody maturation to generate diverse sets of antibodies with high selectivity and affinity for the target antigen.
Published on 4/8/2013
-
Ziarco: Scratching the allergic itch Ziarco Pharma Ltd. Canterbury, U.K. Technology: Small molecule inhibitors for inflammatory diseases Disease focus: Inflammation, dermatology, autoimmune Clinical status: Phase…
Published on 4/8/2013
-
Pfizer spinout Ziarco believes it has best in class small molecules to treat steroid-refractory inflammatory and allergic diseases.
Published on 4/8/2013
-
Hookipa: Next wave vector Hookipa Biotech AG Vienna, Austria Technology: Viral vector platform to develop prophylactic and therapeutic vaccines Disease focus: Infectious Clinical status: Preclinical Founded: …
Published on 4/1/2013
-
Hookipa's Vaxwave platform is designed to develop replication-defective vectors that can elicit antibody as well as B and T cell immune responses.
Published on 4/1/2013
-
Cleave: Proteasome alternatives Cleave Biosciences Inc. Burlingame, Calif. Technology: Small molecule inhibitors of cellular protein homeostasis Disease focus: Cancer Clinical status: Preclinical Founded: 2010 …
Published on 3/25/2013